BIO.RO Biofarm Bucure
- Market cap
- RON 1.35B
- P/E
- 19.6x
- P/B
- 3.42x
- ROE
- 13.5%
- Dividend yield
- 2.17%
- Fundamental score
- 3.2/5
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.
Is BIO.RO undervalued?
Graham numberBIO.RO trades 72.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Biofarm Bucure fundamental analysis
16 of 22 checks passedROE 1/2
Moderate return on equity (13.5%), between 10% and 20%.
ROA 1/1
Return on assets (8.8%) is above the industry median (3.7%).
Profit Consistency 2/2
Profitable for 7 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 1/1
Last year's EPS growth (35.3%) is above the 5-year average (13.1% a year).
Earnings Growth vs Industry 1/1
Last year's EPS growth (35.3%) is above the industry median (24.7%).
Revenue Growth 1/2
Revenue grew 4.9% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (0.3%), 40% or less.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 1/1
No interest expense reported.
PE vs Market 0/1
PE (19.6x) is above the market median (18.3x).
PE vs Industry 0/1
PE (19.6x) is above the industry median (19.0x).
PBV 0/1
Price to book (3.4x) is above the industry median (2.6x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 66.9, limit 22.5).
PEG 0/1
PEG on 5-year earnings growth is 1.49, above 1.
Dividend Yield 1/2
Dividend yield (2.2%) is above the bottom 25% of dividend payers in the market.
Dividend Stability 1/2
Dividends paid without a cut of more than 10% for 5 years.
Dividend Growth 1/1
Dividends paid grew over the past 5 years.
Payout Ratio 1/1
Payout ratio is 29.0%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Biofarm Bucure stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Biofarm Bucure
Biofarm S.A. manufactures pharmaceutical products. The company's products include cardiovascular, digestive and metabolic, genito-urinary, ophthalmological, endocrine, nervous system, osteo-muscular, respiratory and ENT, multivitamin, antiallergen, and dermatological products. Biofarm S.A. was founded in 1921 and is based in Bucharest, Romania. As of June 24, 2026, Biofarm S.A. operates as a subsidiary of Polpharma SA Pharmaceutical Works.
Full company profileBiofarm Bucure financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Biofarm Bucure annual financial statements (RON; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 195M | 216M | 239M | 277M | 280M | 287M | 319M | 259M |
| Gross Profit | 160M | 178M | 200M | 233M | 232M | 242M | 273M | 229M |
| Operating Income | 61.0M | 63.7M | 68.9M | 79.0M | 77.3M | 78.3M | 107M | 44.4M |
| EBITDA | - | - | - | 94.4M | 98.2M | 101M | 133M | 78.6M |
| Net Income | 50.9M | 54.3M | 60.4M | 70.9M | 77.0M | 74.4M | 101M | 53.3M |
| EPS | 0.05 | 0.06 | 0.06 | 0.07 | 0.08 | 0.08 | 0.10 | 0.05 |
| Balance Sheet | ||||||||
| Total Assets | 347M | 372M | 419M | 467M | 494M | 555M | 637M | 605M |
| Total Liabilities | 89.4M | 80.8M | 86.0M | 86.5M | 59.4M | 77.2M | 88.5M | 210M |
| Shareholders' Equity | 257M | 292M | 333M | 380M | 434M | 478M | 548M | 395M |
| Cash & Short-term Investments | 91.1M | 54.5M | 104M | 82.7M | 20.7M | 61.8M | 115M | 208M |
| Cash Flow | ||||||||
| Operating Cash Flow | 73.0M | 39.5M | 69.2M | 29.0M | 79.8M | 57.6M | 80.5M | 56.5M |
| Capital Expenditure | 19.8M | 27.5M | 21.5M | 30.1M | 29.8M | 23.4M | 14.7M | 19.8M |
| Free Cash Flow | 53.2M | 12.0M | 47.7M | -1.11M | 50.0M | 34.2M | 65.9M | 36.8M |
| Ratios | ||||||||
| ROE | 19.8% | 18.6% | 18.1% | 18.7% | 17.7% | 15.6% | 18.4% | 13.5% |
| ROA | 14.7% | 14.6% | 14.4% | 15.2% | 15.6% | 13.4% | 15.8% | 8.8% |
| Net Profit Margin | 26.1% | 25.1% | 25.2% | 25.6% | 27.5% | 25.9% | 31.5% | 20.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Biofarm Bucure dividends
- Dividend yield
- 2.17%
- Forward dividend
- 0.04 RON
- Payout ratio
- 29.0%
- Ex-dividend date
- Jun 29, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | RON 29.2M | 0.03 | 29.0% |
| 2024 | RON 29.2M | 0.03 | 39.2% |
| 2023 | RON 28.2M | 0.03 | 36.7% |
| 2022 | RON 22.5M | 0.02 | 31.8% |
| 2021 | RON 20.7M | 0.02 | 34.3% |
| 2020 | RON 29.0M | 0.03 | 53.5% |
| 2019 | RON 9.44M | 0.01 | 18.6% |
| 2013 | - | - | - |
| 2012 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Biofarm Bucure
- Insiders 92.74%
- Institutions 0.00%
- Public & others 7.26%
- Shares outstanding 985M
- Free float 476M
Biofarm Bucure company profile
- Company name
- Biofarm Bucure
- Ticker
- BIO.RO
- ISIN
- ROBIOFACNOR9
- Exchange
- Bucharest Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 374
- Fiscal year end
- September
- Address
- 99, Logofatul Tautu Street, Bucharest, Romania, 031212
- Phone
- 40 21 301 0600
- Website
- biofarm.ro
About Biofarm Bucure
Biofarm S.A. manufactures pharmaceutical products. The company's products include cardiovascular, digestive and metabolic, genito-urinary, ophthalmological, endocrine, nervous system, osteo-muscular, respiratory and ENT, multivitamin, antiallergen, and dermatological products. Biofarm S.A. was founded in 1921 and is based in Bucharest, Romania. As of June 24, 2026, Biofarm S.A. operates as a subsidiary of Polpharma SA Pharmaceutical Works.
Biofarm Bucure management
10- Mr. Catalin Constantin VicolCEO & Non-Independent Executive Director · born 1974
- Mr. Mihai ZoescuChief Financial Officer · born 1979
- Mr. Mirel FloricaChief Operations Officer
- Ms. Matei Monica Claudia DobrisanChief Accountant
- Mr. Gheorghe PaceaTechnical Manager
- Mr. Valentin Daniel ConstantinLegal & Investor Relations Manager
- Ms. Ioana GoranescuMarketing Manager
- Ms. Mariana BogdeHuman Resource Manager
- Mr. Rachid El LakisDeputy Chief Executive Officer · born 1996
- Ms. Diana Maria VizitiuControlling & Reporting Department Manager